{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:49:36Z","timestamp":1791874176355,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Varenicline aids in smoking cessation but has also been associated with serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to determine the risks of cardiovascular and neuropsychiatric events after varenicline receipt in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A population-based, self-controlled risk interval study using linked universal health administrative data from the diverse, multicultural population of Ontario, Canada, was conducted. In two separate analyses, new varenicline users between September 1, 2011 and February 15, 2014 were observed from 1 year before to 1 year after varenicline receipt. The relative incidences of cardiovascular and neuropsychiatric hospitalizations and emergency department visits in the 12 weeks after varenicline receipt (the risk interval) compared with the remaining observation period (the control interval) were estimated in two separate fixed-effect conditional Poisson regressions. Sensitivity analyses tested the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Among 56,851 new users of varenicline, 6,317 cardiovascular and 10,041 neuropsychiatric hospitalizations and emergency department visits occurred from 1 year before to 1 year after receipt. The incidence of cardiovascular events was 34% higher in the risk compared with the control interval (relative incidence, 1.34; 95% confidence interval, 1.25\u20131.44). Findings were consistent in sensitivity analyses, most notably in those without any history of previous cardiovascular disease. The relative incidence of neuropsychiatric events was marginally significant in the primary (relative incidence, 1.06; 95% confidence interval, 1.00\u20131.13) but not all sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Varenicline appears to be associated with an increased risk of cardiovascular but not neuropsychiatric events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201706-1204oc","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T09:29:25Z","timestamp":1513762165000},"page":"913-922","source":"Crossref","is-referenced-by-count":30,"title":["Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation"],"prefix":"10.1093","volume":"197","author":[{"given":"Andrea S.","family":"Gershon","sequence":"first","affiliation":[{"name":"Department of Medicine and Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"Department of Medicine"},{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada; and"},{"name":"Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Campitelli","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hawken","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Victor","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Sproule","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada; and"},{"name":"Leslie Dan Faculty of Pharmacy"},{"name":"Department of Psychiatry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kurdyak","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada"},{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada; and"},{"name":"Department of Psychiatry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada; and"},{"name":"Department of Psychiatry"},{"name":"Department of Family and Community Medicine"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Ontario Tobacco Research Unit, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2026032023175792200_bib1","volume-title":"The health consequences of smoking\u201450 years of progress: a report of the Surgeon General, 2014","author":"U.S. Department of Health and Human Services","year":"2014"},{"key":"2026032023175792200_bib2","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"5","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023175792200_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.280","article-title":"Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial","volume":"313","author":"Ebbert","year":"2015","journal-title":"JAMA"},{"key":"2026032023175792200_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"2026032023175792200_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/S0140-6736(16)30272-0","article-title":"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial","volume":"387","author":"Anthenelli","year":"2016","journal-title":"Lancet"},{"key":"2026032023175792200_bib6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1503\/cmaj.110218","article-title":"Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis","volume":"183","author":"Singh","year":"2011","journal-title":"CMAJ"},{"key":"2026032023175792200_bib7","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/appi.ajp.2013.12121599","article-title":"Varenicline, smoking cessation, and neuropsychiatric adverse events","volume":"170","author":"Gibbons","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2026032023175792200_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2213-2600(15)00320-3","article-title":"Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study","volume":"3","author":"Kotz","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2026032023175792200_bib9","doi-asserted-by":"crossref","first-page":"e002849","DOI":"10.1161\/JAHA.115.002849","article-title":"Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Sterling","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026032023175792200_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.113.003961","article-title":"Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis","volume":"129","author":"Mills","year":"2014","journal-title":"Circulation"},{"key":"2026032023175792200_bib11","first-page":"e2856","article-title":"Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis","volume-title":"BMJ","author":"Prochaska","year":"2012"},{"key":"2026032023175792200_bib12","first-page":"h1109","article-title":"Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis","volume-title":"BMJ","author":"Thomas","year":"2015"},{"key":"2026032023175792200_bib13","first-page":"h2388","article-title":"Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study","volume-title":"BMJ","author":"Molero","year":"2015"},{"key":"2026032023175792200_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"2026032023175792200_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026032023175792200_bib16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barr\u00e9 syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2026032023175792200_bib17","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"2026032023175792200_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jama.2014.11432","article-title":"Combination long-acting \u03b2-agonists and inhaled corticosteroids compared with long-acting \u03b2-agonists alone in older adults with chronic obstructive pulmonary disease","volume":"312","author":"Gershon","year":"2014","journal-title":"JAMA"},{"key":"2026032023175792200_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","article-title":"Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease","volume":"173","author":"Gershon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026032023175792200_bib20","first-page":"183","article-title":"Identifying patients with physician-diagnosed asthma in health administrative databases","volume":"16","author":"Gershon","year":"2009","journal-title":"Can Respir J"},{"key":"2026032023175792200_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/15412550903140865","article-title":"Identifying individuals with phys[i]cian diagnosed COPD in health administrative databases","volume":"6","author":"Gershon","year":"2009","journal-title":"COPD"},{"key":"2026032023175792200_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"},{"key":"2026032023175792200_bib23","first-page":"e18","article-title":"Accuracy of administrative databases in identifying patients with hypertension","volume":"1","author":"Tu","year":"2007","journal-title":"Open Med"},{"key":"2026032023175792200_bib24","author":"U.S. Food and Drug Administration"},{"key":"2026032023175792200_bib25","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"key":"2026032023175792200_bib26","volume-title":"Data quality documentation for external users: Discharge Abstract Database, 2010\u20132011","author":"Canadian Institute for Health Information","year":"2011"},{"key":"2026032023175792200_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/pds.3337","article-title":"Drug safety studies and measures of effect using the self-controlled case series design","volume":"22","author":"Wilson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026032023175792200_bib28","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1503\/cmaj.151510","article-title":"Managing smoking cessation","volume":"188","author":"Reid","year":"2016","journal-title":"CMAJ"},{"key":"2026032023175792200_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1001\/jama.290.1.86","article-title":"Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review","volume":"290","author":"Critchley","year":"2003","journal-title":"JAMA"},{"key":"2026032023175792200_bib30","doi-asserted-by":"crossref","first-page":"e92286","DOI":"10.1371\/journal.pone.0092286","article-title":"Validity of myocardial infarction diagnoses in administrative databases: a systematic review","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS One"},{"key":"2026032023175792200_bib31","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"key":"2026032023175792200_bib32","doi-asserted-by":"crossref","first-page":"e104519","DOI":"10.1371\/journal.pone.0104519","article-title":"Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS One"},{"key":"2026032023175792200_bib33","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/add.12165","article-title":"Use of varenicline versus bupropion and risk of psychiatric adverse events","volume":"108","author":"Pasternak","year":"2013","journal-title":"Addiction"},{"key":"2026032023175792200_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.96.4.1089","article-title":"Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke","volume":"96","author":"Lightwood","year":"1997","journal-title":"Circulation"},{"key":"2026032023175792200_bib35","author":"U.S. Food and Drug Administration"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/7\/913\/67122944\/ajrccm_197_7_913.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/197\/7\/913\/67122944\/ajrccm_197_7_913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:18:13Z","timestamp":1774063093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/197\/7\/913\/8498664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201706-1204oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,4,1]]}}}